Tenax Therapeutics, Inc. (NASDAQ:TENX) Sees Large Increase in Short Interest

Tenax Therapeutics, Inc. (NASDAQ:TENX) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 419,500 shares, a growth of 93.1% from the January 31st total of 217,200 shares. Based on an average trading volume of 50,200 shares, the short-interest ratio is currently 8.4 days. Approximately 14.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Tenax Therapeutics

Several hedge funds have recently modified their holdings of TENX. Janus Henderson Group PLC acquired a new stake in shares of Tenax Therapeutics in the fourth quarter worth approximately $1,026,000. Vestal Point Capital LP purchased a new stake in shares of Tenax Therapeutics during the third quarter valued at approximately $288,000. Stonepine Capital Management LLC purchased a new stake in shares of Tenax Therapeutics during the third quarter valued at approximately $173,000. Sphera Funds Management LTD. purchased a new stake in shares of Tenax Therapeutics during the third quarter valued at approximately $101,000. Finally, Millennium Management LLC purchased a new stake in shares of Tenax Therapeutics during the fourth quarter valued at approximately $166,000. 1.67% of the stock is owned by institutional investors and hedge funds.

Tenax Therapeutics Price Performance

Shares of TENX traded down $0.05 during mid-day trading on Friday, hitting $5.96. The company had a trading volume of 6,182 shares, compared to its average volume of 39,092. The business’s 50-day simple moving average is $6.42 and its 200-day simple moving average is $5.11. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.